2-(4-Nitrophenyl)imidazo[1,2-a]pyridine-8-carboxamide | 353456-66-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-Nitrophenyl)imidazo[1,2-a]pyridine-8-carboxamide
• CAS: 353456-66-3
• 化学式: C₁₄H₁₀N₄O₃
• 分子量: 282.258
• InChiKey: KJXKZYFVIFJACM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-Nitrophenyl)imidazo[1,2-a]pyridine-8-carboxamide 在 palladium-carbon 作用下， 生成 2-(4-Aminophenyl)imidazo[1,2-a]pyridine-8-carboxamide
  参考文献：
  名称：

  Heterocyclic compounds and their use as parp inhibitors

  摘要：

  本发明涉及化合物的公式（I），其中：A1或A2代表CONH2，而另一个基团A2或A1代表氢，氯，氟，溴，碘，C1-C6烷基，OH，硝基，CF3，CN，NR11R12，NH-CO-R13，O-C1-C4烷基；X1可以表示N和C-R2；独立于X1的X2可以表示N和C-R2；R2可以表示氢，C1-C6烷基，C1-C4烷基苯基，苯基；B可以表示最多具有15个碳原子的不饱和，饱和或部分不饱和的单环，双环或三环环，具有最多14个碳原子和0至5个氮原子，0至2个氧原子或0至2个硫原子的不饱和，饱和或部分不饱和的单环，双环或三环环，每个仍可用R4和最多3个相同或不同的基团R5取代；R1，R4，R5，R11-R13具有权利要求1所述的含义。本发明还涉及所述化合物的互变异构体形式，可能的对映异构体和顺反异构体形式，它们的前药和它们作为PARP抑制剂的用途。

  公开号：

  US20030134843A1

文献信息

• Heterocyclic compounds and their use as PARP inhibitors
  申请人：Abbott GmbH & Co. KG

  公开号：US07041675B2

  公开（公告）日：2006-05-09

  The invention relates to compounds of the formula I and the tautomeric forms, possible enantiomeric and diasteromeric forms thereof, and prodrugs thereof, and use thereof as PARP inhibitors.

  本发明涉及公式I的化合物及其互变异构体、可能的对映异构体和二对映异构体形式，以及它们的前药，并将其用作PARP抑制剂。
• USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20180071244A1

  公开（公告）日：2018-03-15

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
• USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER
  申请人：Bacha Jeffrey A.

  公开号：US20190091195A1

  公开（公告）日：2019-03-28

  Substituted hexitol derivatives such as dianhydrogalactitol are useful in the treatment of various neoplastic pathologies. Said pathologies include glioblastoma multiforme, non-small-cell lung carcinoma (NSCLC), ovarian cancer, and leptomeningeal carcinomatosis. The anti-neoplastic activity of dianhydrogalactitol is demonstrated to be due to its activity as an alkylating agent that creates N 7 methylation and inter-strand DNA crosslinks. The hexitol derivatives may be used alone or in combination with other anti-neoplastic agents.
• US7041675B2
  申请人：——

  公开号：US7041675B2

  公开（公告）日：2006-05-09
• [EN] USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE<br/>[FR] UTILISATION DE DIANHYDROGALACTITOL OU DE DÉRIVÉS ET D'ANALOGUES DE CELUI-CI POUR LE TRAITEMENT D'UN CARCINOME NON À PETITES CELLULES, D'UN GLIOBLASTOME ET D'UN CARCINOME DE L'OVAIRE PAR INDUCTION DE LÉSIONS DE L'ADN ET BLOCAGE DU CYCLE CELLULAIRE
  申请人：DEL MAR PHARMACEUTICALS

  公开号：WO2017042634A2

  公开（公告）日：2017-03-16

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma, non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation and inter-strand crosslinks that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or synergistic effects. Dianhydrogalactitol can be used for treatment of leptomeningeal carcinomatosis.